Evidence map›Paper›PMID 33509107›Full record

Trial reportBMC nephrology2021

Substitution of citrate with tissue plasminogen activator (rt-PA) for catheter lock does not improve patency of tunnelled haemodialysis catheters in a randomised trial.

Pavlina Richtrova, Jan Mares, Lukas Kielberger, Jan Klaboch, Jaromir Eiselt, Tomas Reischig

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Strategies to Prevent Hemodialysis Catheter Dysfunction.Journal of the American Society of Nephrology : JASN · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Pavlina RichtrovaDepartment of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and Teaching Hospital in Pilsen, Alej Svobody 80, 304 60, Plzen, Czech Republic. richtrovap@fnplzen.cz.ORCID 0000-0002-6957-5334
Jan MaresDepartment of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and Teaching Hospital in Pilsen, Alej Svobody 80, 304 60, Plzen, Czech Republic.
Lukas KielbergerDepartment of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and Teaching Hospital in Pilsen, Alej Svobody 80, 304 60, Plzen, Czech Republic.
Jan KlabochDepartment of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and Teaching Hospital in Pilsen, Alej Svobody 80, 304 60, Plzen, Czech Republic.
Jaromir EiseltDepartment of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and Teaching Hospital in Pilsen, Alej Svobody 80, 304 60, Plzen, Czech Republic.
Tomas ReischigDepartment of Internal Medicine I, Faculty of Medicine in Pilsen, Charles University, and Teaching Hospital in Pilsen, Alej Svobody 80, 304 60, Plzen, Czech Republic.
Charles University · CZ

Funding

Ministry of Education, Youth and Sports od the Czech Republic CZ.02.1.01/0.0/0.0/16_019/0000787Ministry of Education, Youth and Sports of the Czech Republic MSM0021620819Ministry of Education, Youth, and Sports of the Czech Republic Progres Q39
6 · The paper itself

Abstract

backroundThe study aim was to establish if substitution of citrate with rt-PA for catheter lock once weekly can reduce the incidence of catheter-related blood stream infections (CR-BSI) or improve patency of tunneled haemodialysis catheters.

methodsAll incident patients undergoing insertion of a tunneled haemodialysis catheter were screened and included except those suffering infection or using oral anticoagulation. Study participants were randomized into two arms according to the solution applied as catheter lock: receiving either trisodium citrate (Citra-LockTM 4%) only or rt-PA (Actilyse® 1 mg/ml) on the middle session each week with citrate used on the first and third sessions. The incidence of CR-BSI (confirmed by positive blood culture), catheter non-function (complete obstruction), and malfunction (blood flow < 250 ml/min) was recorded. Statistical significance was tested with ANOVA, post hoc analysis was performed by means of multiple linear regression.

resultsTotally, 18 patients were included and followed during 655 haemodialysis sessions. No episode of CR-BSI was detected while 6 catheter non-functions (0.9% sessions) and 101 malfunctions (15.4% sessions) were recorded. The incidence of both events was equal between the study arms: 4 non-functions and 55 malfunctions in the rt-PA arm and 2 non-functions and 46 malfunctions in the citrate arm (p = 0.47 and p = 0.24, respectively). Additionally, the mean blood flow achieved did not differ significantly between the arms: 326 ± 1,8 and 326 ± 1,9 ml/min (p = 0.95) in rt-PA and citrate arms, respectively. Post hoc analysis identified time elapsed since previous session (β = 0.12, p = 0.005) and malfunction on previous session (β = 0.25, p < 0.001) as significant factors affecting the occurrence of malfunction. By contrast, the study arm, rt-PA application on previous session, and catheter vintage did not enter the model.

conclusionSubstitution of citrate with rt-PA for catheter lock does not reduce the incidence of catheter malfunction neither does it affect the blood flow achieved during haemodialysis. Catheter patency is related rather to the time interval between sessions and to previous malfunction (thus probably reflecting undefined individual factors). The incidence of CR-BSI within pre-selected haemodialysis population is sporadic (less than 1 per 4.3 patient years in our sample).

trial registrationAustralian New Zealand Clinical Trials Registry, ACTRN12612000152820 . Retrospectively registered 03/02/2012.

Indexed as

Central Venous CathetersAgedAged, 80 and overCitratesDouble-Blind MethodDrug SubstitutionFemaleFibrinolytic AgentsHumansMaleMiddle AgedProspective StudiesRenal DialysisTissue Plasminogen ActivatorVascular PatencyCitratesFibrinolytic AgentsTissue Plasminogen Activatortrisodium citrate

Identifiers

PMID33509107
PMCPMC7845091
OpenAlexW3121186973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.